Chlorophyll for Skin Health

Verdict: Weak, disputed; popular oral form unproven

Evidence that chlorophyll helps skin is weak and disputed: a few small, mostly industry-funded studies of topical copper chlorophyllin and chlorophyll-based light therapy show modest signals for acne and photoaging, but the heavily marketed oral "chlorophyll water" has no supporting clinical trials at all. Treat it as a low-evidence cosmeceutical, not a proven skin treatment, and note real safety caveats.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

This earns a weak, disputed grade because the human evidence is small, low-quality, and only covers applied-to-skin or light-therapy uses, not the oral supplements consumers actually buy. The one genuine randomized trial (PMID 24930587, n=24) found chlorophyll-a plus LED light beat LED alone for acne, but it tests chlorophyll as a light-activated agent, not a standalone product, and its comparator was light-only rather than a sham. An earlier split-face pilot (PMID 21254857) gave only a preliminary positive signal.

The remaining studies are fragile. Two single-arm pilots of topical copper chlorophyllin (PMID 26091384 for acne and pores; PMID 25844615 for photodamage, each n=10) improved scores versus baseline but had no placebo, so regression and vehicle effects cannot be excluded. A 4-person biopsy study (PMID 27524916) raised skin-repair biomarkers, which supports plausibility but not visible benefit. All three were funded by the product's developer, with overlapping authors, a clear conflict of interest.

Authorities reinforce caution rather than endorsement. The FDA permits sodium copper chlorophyllin only as a color additive and has warned sellers making acne and detox claims for liquid chlorophyll; EFSA rejected chlorophyll health claims, while WHO's favorable rating concerns colorant safety, not efficacy. Cleveland Clinic notes the roughly 10-person study sizes and warns chlorophyllin can increase sunburn risk; Mayo, Harvard, the AAD, and the UK NHS do not address it, and Examine has no entry.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.42
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
70%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.40
L5 Clinical bodiesAuthoritative stance
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.423
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Photodynamic therapy using chlorophyll-a in the treatment of acne vulgaris: a randomized, single-blind, split-face study
PMID: 24930587 2014 RCT (open-label) n = 24
Finding: Chlorophyll-a PDT side showed significantly greater reductions in acne lesion counts, acne severity grade, and sebum level vs LED-only side. Specific p-values not stated in abstract; authors describe differences as statistically significant.
View on PubMed
Pilot study on photodynamic therapy for acne using chlorophyll: evaluator-blinded, split-face study
PMID: 21254857 2012 RCT (open-label)
Finding: Pilot study reported improvement on chlorophyll-PDT side vs control side; specific quantitative results not in abstract. Established proof-of-concept that subsequent larger split-face study (Song 2014, PMID 24930587) built upon.
🟠 Limited quality
View on PubMed
Pilot Study of Topical Copper Chlorophyllin Complex in Subjects With Facial Acne and Large Pores
PMID: 26091384 2015 Cohort n = 10
Finding: All clinical efficacy parameters showed statistically significant improvements over baseline at week 3. Product well tolerated. No placebo or active comparator arm — cannot rule out regression to mean / placebo effect / vehicle effect.
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Assessment of the safety and efficacy of topical copper chlorophyllin in women with photodamaged facial skin
PMID: 25844615 2015 Cohort n = 10
Finding: All clinical efficacy parameters showed statistically significant improvements over baseline at week 8. Product well tolerated. Subject self-assessment ratings were favorable.
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Ability of sodium copper chlorophyllin complex to repair photoaged skin by stimulation of biomarkers in human extracellular matrix
PMID: 27524916 2016 RCT (open-label) n = 4
Finding: Chlorophyllin gel significantly increased fibrillin/amyloid P (mean 1.25 vs control 0.25, p=0.002) and epidermal mucins (1.25 vs 0.50, p=0.007). No statistical difference vs tretinoin reference (positive control). Mechanistic / surrogate-biomarker study — not a clinical wrinkle/photoaging endpoint trial.
🟠 Limited quality ⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
The color additive sodium copper chlorophyllin may be safely used to color dentifrices that are drugs and cosmetics in amounts not to exceed 0.1 percent. source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
銅葉綠素及銅葉綠素鈉均為我國及國際規範所准許使用之食品添加物……銅葉綠素為國際規範准許使用之食品添加物著色劑,但各國均未准許使用於『食用油脂產品』中。如標示、宣稱為『天然色素』、『天然葉綠素』等字樣,涉屬標示不實。 source↗
L4e WHO
Neutral
ADI NOT LIMITED (JECFA 13, 1969); INS 140 — Chlorophylls. Report: NMRS 46/TRS 445-JECFA 13/10. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-skin-health-INT-chlorophyll-001 繁體中文版 →